ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case
ArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
ArriVent BioPharma Reports Full Year 2025 Financial Results
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Moderate Buy” by Analysts
Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact
$207B Market Shift: The Race for Fast Track Approval in Oncology
ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
12,735 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by AXQ Capital LP
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Moderate Buy” by Analysts
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
New Strong Sell Stocks for July 21st
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
ArriVent BioPharma Reports First Quarter 2025 Financial Results
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
ArriVent BioPharma Reports Full Year 2024 Financial Results
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
ArriVent BioPharma Reports First Quarter 2024 Financial Results
ArriVent Appoints Kristine Peterson to its Board of Directors
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
ArriVent BioPharma Reports Full Year 2023 Financial Results
Insider Buying at These Biotechs Is Huge
ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment